A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Conditions: Malignant Rhabdoid Tumors (MRT); Rhabdoid Tumors of the Kidney (RTK); Atypical Teratoid Rhabdoid Tumors (ATRT); Selected Tumors With Rhabdoid Features; Synovial Sarcoma; INI1-negative Tumors; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2015 Category: Research Source Type: clinical trials
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Conditions: Rhabdoid Tumors; INI1-negative Tumors; Synovial Sarcoma; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2015 Category: Research Source Type: clinical trials
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Conditions: Malignant Rhabdoid Tumors (MRT); Rhabdoid Tumors of the Kidney (RTK); Atypical Teratoid Rhabdoid Tumors (ATRT); Selected Tumors With Rhabdoid Features; Synovial Sarcoma; INI1-negative Tumors; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2015 Category: Research Source Type: clinical trials
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Conditions: Rhabdoid Tumors; INI1-negative Tumors; Synovial Sarcoma; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2015 Category: Research Source Type: clinical trials
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Conditions: Malignant Rhabdoid Tumors (MRT); Rhabdoid Tumors of the Kidney (RTK); Atypical Teratoid Rhabdoid Tumors (ATRT); Selected Tumors With Rhabdoid Features; Synovial Sarcoma; INI1-negative Tumors; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2015 Category: Research Source Type: clinical trials
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Conditions: Rhabdoid Tumors; INI1-negative Tumors; Synovial Sarcoma; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2015 Category: Research Source Type: clinical trials
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Conditions: Malignant Rhabdoid Tumors (MRT); Rhabdoid Tumors of the Kidney (RTK); Atypical Teratoid Rhabdoid Tumors (ATRT); Selected Tumors With Rhabdoid Features; Synovial Sarcoma; INI1-negative Tumors; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2015 Category: Research Source Type: clinical trials
Taa-specific ctls for solid tumors (tactasom)
Conditions: Bladder Cancer; Breast Cancer; Colorectal Cancer; Endometrial Cancer; Gastric Cancer; Glioma/Medulloblastoma; Head and Neck Cancer; HCC; Lung Cancer; Melanoma; Neuroblastoma; Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc); Pancreatic Cancer; Prostate Cancer; Renal Cell Carcinoma; Thyroid CancerIntervention: Biological: TAA-Specific CTLsSponsors: Baylor College of Medicine; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of MedicineNot yet recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2014 Category: Research Source Type: clinical trials
